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Radiotherapy (RT) has been considered a local modality and outcomes have emphasized
local and regional control of tumors. Recent data suggests that RT may activate the immune
system and the combination of radiation therapy and immune therapies may have the
potential to improve both local and distant control of tumor deposits. Below we review
principals underlying the concepts of combining both modalities.
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INTRODUCTION
The utility of radiotherapy (RT) as an anti-tumor agent is usu-
ally based on the fact that radiation can induce irreparable DNA
damage, and eventually cell death through a variety of mecha-
nisms including; mitotic catastrophe, apoptosis, senescence, and
autophagy (Rupnow and Knox, 1999; Eriksson and Stigbrand,
2010). Improvements in the clinical practice of RT were histor-
ically aimed at technically achieving maximal tumor cell killing
while balancing damage to normal tissues. However, over the past
decade RT has been the subject of a steady conceptual and experi-
mental reinvention that has broadened both our understanding of
themechanisms bywhichRTmediates tumor eradication andpos-
sibilities for synergistic combinations with emerging anti-cancer
therapies. Of particular relevance to this review is the ﬁnding
that in a variety of preclinical animal models adaptive immu-
nity plays a deﬁning role in the efﬁcacy of RT (Lugade et al.,
2005; Lee et al., 2009). The mechanisms underlying the capac-
ity of RT to engage the immune system are the subject of intense
scientiﬁc inquiry. Published data demonstrate that RT can induce
or augment all phases of the T cell response from T cell prim-
ing, trafﬁcking, and effector responses within the tumor, which
endorses a natural alignment of radiation and immunotherapy.
The data from preclinical models may overemphasize the role of
adaptive immunity in RT as a single modality, which may explain
the paucity of supporting clinical data. Only relatively recently has
there been a meaningful effort to assess immunological correlates
in the course of traditional RT. Regardless of the overall contri-
bution of adaptive immunity to RT, at the very least the immune
system is poised to be a powerful ally with a demonstrated capac-
ity to augment the anti-tumor effects of RT. Therefore, several
aspects of clinical RT warrant reconsideration with respect to the
role of endogenous anti-tumor immunity especially in light of
combinatorial treatment strategies that incorporate immunother-
apy. In this review, we will discuss these and other aspects
of RT that could affect the proposed synergistic relationship
between RT and immunotherapy and also highlight some
novel strategies that aim to further exploit the immunogenicity
of RT.
IMMUNE RECOGNITION OF TUMORS
The principals of tumor immunology were originally established
by pioneering work of Burnet and Thomas when they pro-
posed that nascent tumors can be recognized and eliminated
by the host immune system in a process they termed “cancer
immunosurveillance” (reviewed in Dunn et al., 2006). By infer-
ence, immunosurveillance governs the capacity of the immune
system to “recognize” the tumor. From simpliﬁed viewpoint, this
interaction can be divided into two processes whereby the immune
system is ﬁrst“alerted”to the presence of cells undergoing neoplas-
tic transformation through stress or danger signals, and second,
is equipped to directly interact with neoplastic cells to mediate
destruction. Although considerable debate still exists regarding
whether immunosurveillance exists in human and mouse tumors,
the underlying principles that deﬁne the capacity of the immune
system to speciﬁcally recognize tumors remain unchanged. There-
fore, whether or not the emergence of clinically detectable tumors
is reduced by immune-mediated mechanisms does not preclude
subsequent immune recognition that could occur during the clin-
ical treatment of tumors. A logical extension of the principles
of cancer immunosurveillance, therefore, lies in the hypothe-
sis that successful treatment of established tumors, as potential
products of failed or blunted surveillance, could be achieved by
rekindling immune recognition. This hypothesis is the founda-
tion of the ﬁeld of tumor immunology and its applied counterpart
cancer immunotherapy. Cancer immunotherapy represents the
use of agents proposed to amplify the host immune response to
established tumors (Pardoll and Drake, 2012). Radiation therapy
and immunotherapy may be natural partners given that radia-
tion possesses immunomodulatory effects at multiple points in
the processes of T cell priming and effector function. We will
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review literature regarding the immunomodulatory properties of
radiation and discuss available data dealing with the effect of dose
and fractionation schedules on various aspects of the anti-tumor
immune response.
EFFECTS ON TUMOR ANTIGENICITY
The ﬁrst major requirement for tumor-speciﬁc adaptive immu-
nity is the availability and immunogenicity of tumor antigens. A
plethora of tumor antigens have been deﬁned across a wide array
of tumor types and they fall into three broad categories: (1) viral
proteins, (2) mutated versions of self-proteins that include point
mutations and oncogenic fusion proteins generated by recombina-
torial events, or (3) non-mutated self-proteins enriched in tumor
cells but with shared expression on non-tumor tissue (for review,
see Jäger et al., 2001). Melanoma differentiation antigens and can-
cer testis (CT) antigens are the best characterized tumor-associated
antigens (Engelhard et al., 2002; Scanlan et al., 2002). The etiology
of tumor antigens has important implications on immunogenic-
ity. Non-mutated tumor-associated antigens are self-antigens that
are subject to immunological tolerance mechanism that drasti-
cally diminish the peripheral repertoire of high-afﬁnity T cells
capable of recognizing these antigens. However, tumor-associated
antigens offer a convenient clinical target both for therapeutic
vaccination and immunological assessment due to a high fre-
quency of expression across many tumor types. Mutated tumor
antigens represent the most unique antigens that, based on their
extrathymic expression, would be excluded from central tolerance.
Therefore, T cells expressing high-afﬁnity T cell receptors (TCRs)
speciﬁc for these antigens are likely to be present in the peripheral
pool. Identiﬁcation and vaccination against such antigens, how-
ever, requires sophisticated high-throughput screening methods
to identify mutations and sift out the potential antigenic pep-
tides with sufﬁcient binding to major histocompatibility (MHC)
antigens to mediate efﬁcient presentation. Notable exceptions
that can be readily identiﬁed are antigens generated by mutated
oncogenic proteins that have high association with some cancers
(Boon, 1996). Non-mutated tumor-associated antigens, on the
other hand, are readily identiﬁed by established screening meth-
ods and are widely expressed across tumor types. Such antigens
are often accompanied by some degree of T cell tolerance that
dampens endogenous immunity (Engelhard et al., 2002). Never-
theless, clinically viable vaccination strategies have been developed
that can induce durable T cell responses against tumor-associated
antigens, and even low-avidity T cells that escape negative
selection can mediate anti-tumor effects if properly activated
(Uchi et al., 2006).
With regard to tumor-antigen expression, local high dose abla-
tive (15–20 Gy) radiation has been shown to directly upregulate
the expression of some tumor antigens including tumor anti-
gens associated with viral transformation (Santin et al., 1998), and
CT antigens (Sharma et al., 2011). A mechanistic basis for these
changes was reported by Reits et al. (2006) who demonstrated
that tumor cell irradiation leads to increased protein translation
as a consequence of mTOR activation. Furthermore, radiation
increased the degradation of cellular proteins as a result of direct
free radical-mediated damage. The resulting increase in the intra-
cellular pool of available peptides augments MHC loading and
productive antigen presentation. Interestingly, dose-dependent
effects of radiation were observed in terms of both the magnitude
and duration of intracellular peptide availability. Single doses of
higher than 4 Gy were required to dramatically enhance MHC
class I surface expression, and a single dose of 25 Gy induced
the most robust expression, which correlated with measurements
of intracellular peptide levels. Together these mechanisms could
overcome the poor antigenicity of some tumors in instances where
availability of tumor antigens is a limiting factor to the induc-
tion of tumor antigen-speciﬁc T cells. Although, the mechanisms
uncovered by Reits et al. (2006) provide an interesting mechanism
by which local RT could enhance local T cell-mediated recogni-
tion, whether or not this mechanism plays any role in augmenting
endogenous immunity remains unknown. It would be interesting
to know whether the intermediate effect of local radiation alone
on tumor growth in their model could be abrogated by systemic
CD8T cell depletion. Nevertheless, these studies suggest that larger
doses of radiation are more potent at increasing tumor antigenic-
ity, however, the effect of smaller daily fractionated doses was not
investigated. It is possible that daily doses of less than 2 Gy, such
as those used in traditional RT, might eventually result in a cumu-
lative effect that could eventually approach the large single doses
used by the authors given the kinetics of increased protein degra-
dation. Notably, if the effect of radiation on MHC class I surface
expression is indeed mediated through alleviation of the normally
limiting pool of available intracellular peptides, then these effects
would presumably be unrelated to intrinsic tumor cell radiosen-
sitivity and therefore uniform across most tumor cells unless the
efﬁciency of targeted protein degradation varies widely. In order
to make these peptides available as substrates for T cell priming,
however, transfer to professional antigen presenting cells (APCs)
must occur in such a manner that stimulates efﬁcient capture and
intracellular processing within the APC to yield MHC:peptide
complexes that are subsequently presented to T cells, a process
termed antigen cross-presentation.
RADIATION-MEDIATED “DANGER SIGNALS” AND
CROSS-PRESENTATION OF TUMOR ANTIGENS
The innate immune system is equipped with many molecular sen-
sors that facilitate the recognition of unique molecular patterns
found in the myriad pathogens present in the environment. These
sensors are localized to subcellular locations including the plasma
membrane, endosomes, and the cytoplasm poised to detect invad-
ing pathogens. Charles Janeway proposed a cellular recognition
system, consisting of receptors that could exclusively recognize
unique features of pathogens (pathogen-associated molecular pat-
terns, PAMPs), that formed the central basis for“self”vs“non-self”
discrimination. This pathogen recognition system was thought
to explain why antigens derived from pathogens elicit potent
adaptive immune responses, and self-antigens are “ignored.” A
highly provocative amendment to this hypothesis was proposed
by Polly Matzinger, who hypothesized that tissue injury in the
absence of pathogens could elicit innate immune recognition
through stress signals that she collectively termed “Danger Sig-
nals” (Matzinger, 1994). It is now recognized that many of these
same receptors do double duty and can recognize endogenous
molecular signals emanating from stressed or dying cells in the
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absence of pathogens (Matzinger, 2002). Thus, the host actually
senses “danger” in the form of cellular stress and tissue injury
rather than sensing the presence of a pathogen speciﬁcally. The
endogenous ligands are termed molecular“alarmins”and together
with PAMPs they are collectively termed“danger signals” (Bianchi,
2006). Alarmins function as endogenous adjuvants that form an
essential bridge between innate inﬂammatory responses and the
initiation of tumor-speciﬁc adaptive immunity following treat-
ment of tumors with local radiation. The exposure or release of
danger signals also depends on the type of cell death that occurs
and many open questions remain regarding the relative contribu-
tions of each to the immunogenicity of radiation-mediated tumor
cell death.
High mobility group box 1 (HMGB1) is a prototypical
“alarmin” that was shown to be a central mediator in the immuno-
genicity of dying tumor cells following irradiation (Apetoh et al.,
2007). Normally a nuclear protein associated with chromatin,
extracellular release of HMGB1 from dying tumor cells was
demonstrated to engage Toll-like receptor 4 (TLR4) expressed by
dendritic cells (DCs) to facilitate their activation, maturation, and
capacity to efﬁciently prime tumor antigen-speciﬁc CD8+ T cells
(T cell cross-priming). Since TLR4 binds ligands at the plasma
membrane, HMGB1 must be released into the extracellular space
in order to engage TLR4. Extracellular exposure could be medi-
ated by direct necrotic cell death or secondary necrosis of lingering
apoptotic bodies that are inefﬁciently cleared. Conceptually, apop-
totic death of tumor cells is predicted to conceal HMGB1 from
TLR4-mediated recognition (Bianchi and Manfredi, 2007). How-
ever radiation-mediated cell death of most solid tumors is thought
to predominantly occur through inductionof senescence, necrosis,
or mitotic catastrophe. An exception is hematopoietic tumors that
frequently undergo rapid induction of apoptosis following radia-
tion exposure (Rupnow and Knox, 1999; Eriksson and Stigbrand,
2010). Radiation-mediatedmitotic death shares featureswith both
apoptosis and necrosis, however, the prevailing view places it more
closely associated with necrosis. More recently, a speciﬁc receptor
for necrotic cellswas cloned and characterized. DNGR-1/CLEC9A,
a c-type lectin, was shown to be essential for the induction of adap-
tive immunity to necrotic cells (Sancho et al., 2009). Importantly,
interaction of DNGR-1with necrotic cells did not affect the uptake
of necrotic debris, but instead regulated the capacity of DCs to
cross-present antigens contained therein. Furthermore, DNGR-1
expression was shown to speciﬁcally identify mouse and human
DCs that express the transcription factor Batf3 and are special-
ized for cross-presentation of antigens to CD8+ T cells (Poulin
et al., 2010, 2012; Schreibelt et al., 2012). The ligand for DNGR-
1 was recently identiﬁed to be ﬁlamentous actin (F-actin) that
is exposed upon the loss of membrane integrity characteristic of
necrotic cell death (Ahrens et al., 2012). These concepts may be
related to radiation induction of antigen processing and remain to
be studied.
In addition to ligands that promote DC activation and sub-
sequent maturation, several other danger signals contribute to
immunological recognition of dying tumor cells. In particular,
nucleotides released by apoptotic cells function as a chemotactic
signal for phagocytic myeloid cells including DCs by stimulating
the P2RY2 purinergic receptor (Elliott et al., 2009). Extracellular
ATP can also function through P2RX7 purinergic receptors to
initiate NLRP3 inﬂammasome activation and subsequent IL-1β
production that were all shown to be required for the induc-
tion of tumor antigen-speciﬁc CD8+ T cells following challenge
with dying tumor cells (Ghiringhelli et al., 2009). Finally, surface
translocation of the ER resident protein calreticulin (together with
ERP57) was shown to be an essential signal for efﬁcient uptake
of dying tumor cells by APCs and therefore a critical regula-
tor of immunogenic cell death following tumor cell exposure to
γ-irradiation (Obeid et al., 2006, 2007). Calreticulin exposure pro-
ceeds as a preapoptotic event that could be partially blocked by
caspase inhibition, however, it is unclear whether translocation of
calreticulin is a widely observed phenomenon across all modes of
cell death induced by irradiation or if it is unique to cells destined
to undergo apoptosis.
Taken together, the radiation-induced release of tumor antigens
must be accompanied by coincident release and recognition of
danger signals in order to efﬁciently generate tumor-speciﬁcCTLs.
The ability of radiation to promote tumor antigen release has been
demonstrated in several models, however, the type and magnitude
of danger signal release is quite variable and may still provide
suboptimal maturation signals to APCs. The coadministration of
exogenous danger signals in the context of tumor irradiation has
been shown to augment the immunogenicity of RT in both pre-
clinical animal models and clinical trials. In particular, treatment
of mice with a synthetic TLR9 agonist resulted in both enhanced
local control and reduced distant metastasis when combined with
single highdoseRT (Zhang et al., 2012). Augmented tumor control
was associated with enhanced activation and cytokine produc-
tion by CD8+ T cells and enhanced deposition of tumor-speciﬁc
Ig in the tumor bed. Furthermore, a phase I/II clinical trial
demonstrated that lymphoma patients that received combined
radiation and TLR9 agonist had improved clinical responses sug-
gesting that supplemental danger signals in the context of tumor
irradiation my drive more potent host T cell responses (Brody
et al., 2010). Experiments that further elucidate both the unique
and overlapping aspects of radiation-induced danger signals and
exogenous adjuvants on host T cell activation and priming are
needed.
T CELL PRIMING FOLLOWING TREATMENT OF ESTABLISHED
TUMORS WITH LOCAL RT
Data in preclinical models have demonstrated increased prim-
ing of tumor antigen-speciﬁc CD8+ T cells in the draining
lymph node (dLN) several days following treatment of established
tumors with ablative single dose local RT (Lugade et al., 2005;
Lee et al., 2009). Particularly, our group demonstrated enhanced
cross-presentation of tumor antigen by CD11c+ DCs present in
the dLN following migration from the tumor (Lee et al., 2009).
Recently, this mechanism was expanded to incorporate proximal
events in the tumor microenvironment. Local radiation has been
shown to induced rapid recruitment and inﬁltration of leuko-
cytes (Shiao and Coussens, 2010; Burnette et al., 2011). Among
the recruited cells, circulating monocytes can give rise to CD11c+
DCs. Within the irradiated tumor microenvironment these DCs
encounter myriad danger signals and capture antigens from dying
tumor cells through phagocytic receptors (discussed above). Our
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group demonstrated that treatment of tumors with local ablative
RT could greatly enhance the cross-priming capacity of tumor-
inﬁltrating DCs (TIDCs), and this effect was shown to be critically
dependent on type I interferon (IFN) signaling in bone marrow-
derived hematopoietic cells (Burnette et al., 2011). Importantly,
the enhanced cross-priming capacity of TIDC was not simply
dependent on availability of newly liberated tumor antigen, but
rather was dependent on signals unique to the irradiated tumor
microenvironment. The development of DCs in the irradiated
tumor microenvironment that are competent to prime tumor
antigen-speciﬁc T cells precedes the enhanced T cell priming
that we and others have observed in the dLN. These sequen-
tial observations suggest that migration of functional TIDCs to
the dLN drives T cell priming following local RT (Lugade et al.,
2008; Meng et al., 2010; Gupta et al., 2012). Interestingly, type I
IFN was shown to be a critical mediator of spontaneous tumor
antigen-speciﬁc CD8+ T cell priming (Fuertes et al., 2011). More
speciﬁcally, DCs were shown to be the essential targets of type I
IFN signaling to mediated T cell priming and drive tumor immu-
noediting (Diamond et al., 2011). Together these results paint
a compelling picture that local radiation may, in fact, rekindle
central aspects of innate and adaptive immunity to induce sub-
sequent rounds of immunoediting, and in some cases, complete
regression.
T CELL MIGRATION AND EFFECTOR FUNCTION IN THE
TUMOR MICROENVIRONMENT
The tumor microenvironment represents a formidable challenge
to immune-mediated recognition and killing of tumor cells. In
the absence of local RT, strategies aimed at increasing the pool of
tumor antigen-speciﬁc T cells, such as therapeutic vaccination or
adoptive transfer of large numbers of speciﬁc T cells, fails to exert
signiﬁcant effects on tumor outgrowth. However, combining these
strategies with local RT can yield impressive results in preclinical
models (Harris et al., 2008; Takeshima et al., 2010). Therefore, the
capacity of local RT to support immune-mediated tumor regres-
sion extends far beyond the effects of local RT on T cell priming,
and involves local changes that reinforce immunity subsequent to
priming. Local radiation has been shown to facilitate the recruit-
ment of activated T cells to the tumor and induce changes in the
local microenvironment and on tumor cell themselves that can
greatly enhance T cell effector function. RT can upregulate expres-
sion of adhesion molecules, such as VCAM-1, E-selectin, and
ICAM-1, by vascular endothelial cells within the tumor and induce
expression of T cell chemokines that promote T cell adhesion
and extravasation into the tumor microenvironment (Handschel
et al., 1999; Lugade et al., 2008). Both the expression of adhesion
molecules and the production of T cell attractive chemokines are
likely a product of a feedforward mechanism induced by pro-
duction of IFNs in the tumor microenvironment (Lugade et al.,
2008; Meng et al., 2010). In addition, tumor cells can directly
produce CXCL16 following irradiation leading to the recruit-
ment of activated CD8+ CXCR6+ effector cells (Matsumura
et al., 2008; Matsumura and Demaria, 2010). Furthermore, RT
has been shown to induce several changes that directly affect
the ability of effector T cells to efﬁciently recognize and kill
tumor cells.
As previously noted, radiation increases surface expression
of MHC on tumor cells, which increases the likelihood of
a productive interaction with cognate antigen-speciﬁc T cells.
Upregulation of MHC likely occurs through several mechanisms
that coordinately drive robust expression. In addition to the
mechanism proposed by Reits et al. (2006; discussed above),
local radiation has been shown to induce MHC expression
through induction of IFN-β that can signal to tumor cells in
an autocrine/paracrine fashion (Wan et al., 2012). IFN-γ secre-
tion by inﬁltrating effector cells can also further augment MHC
expression and promote T cell-mediated recognition of tumor
cells through cognate TCR:peptide/MHC interactions. Bolstering
the direct TCR-mediated recognition of tumor cells, is the local
expression of ligands for the NKG2D activating receptor. NKG2D
ligands have been shown to be expressed as a consequence of
cellular transformation, are upregulated by cellular stress, and
directly induced by irradiation through activation of the DNA
damage pathway (Gasser et al., 2005). NKG2D is an activating
receptor expressed by NK cells and activated CD8+ T cells that,
upon engagement, can signiﬁcantly increase cytolytic potential
(Markiewicz et al., 2005; González et al., 2008; Champsaur and
Lanier, 2010). Upregulation of NKG2D ligands could be a robust
mechanism for local restimulation of CTL and enhanced cytokine
production, however, the mechanisms regulating expression are
complex and expression among tumors is variable (Nausch and
Cerwenka, 2008). Finally, radiation can upregulate expression of
the FAS death receptor on tumor cells to induce sensitivity to
T cell expressed FAS ligand (Chakraborty et al., 2004). The induced
sensitivity of tumor cells to FAS-mediatedkilling represents aTCR-
independent mechanism for tumor cell killing and can function
as a more potent cytotoxic modality especially in instances where
TCR afﬁnity is low and perforin-mediated cytotoxicity is less efﬁ-
cient (Kessler et al., 1998). The combination of these local effects
likely accounts for a signiﬁcant portion of the interaction with
immunotherapy.
SYNERGY WITH IMMUNOTHERAPY
The immune modulating capacity of RT is clearly multifaceted
and can, in some preclinical models, lead to robust anti-tumor
immunity that can mediate complete tumor regression as a
single modality. However, it has been reported that radiation
could increase some immunosuppressive aspects of the tumor
microenvironment such as regulatory T cell (Treg) accumula-
tion depending on the dose and timing (Kachikwu et al., 2011;
Schaue et al., 2011). Therefore, in order tomaximize the immunos-
timulatory effects of RT, strategies that combine local RT with
immunotherapy are required to generate durable T cells responses
in patients. Among the prospects for targeted therapies that
can directly enhance T cell responses, monoclonal antibodies
that modulate T cell coactivating and coinhibitory receptors, or
their ligands, are the most accessible. Productive T cell prim-
ing and the induction of tolerance are determined by a complex
integration of many stimulatory and inhibitory receptors that
reinforce and dampen the primary TCR:peptide/MHC interac-
tion, respectively. Recently, a monoclonal antibody targeting the
T cell negative regulator, CTLA-4, received FDA approval fol-
lowing a proven survival beneﬁt in a randomized clinical trial of
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patients with metastatic melanoma (Hodi et al., 2010). CTLA-4 is
expressed by activated T cells and functions as a natural regulatory
mechanism to dampen T cell activation and prevent autoimmu-
nity by competitively inhibiting the interaction of CD28 on T cells
with B7-1/B7-2 on APCs (Rudd et al., 2009). CD28 cosignaling
is required for optimal induction of CD25, which together with
IL-2Rβ and common gamma chain, form the high-afﬁnity IL-2
receptor. IL-2 signaling induces both the differentiation and sur-
vival of effector T cells, and the inability to upregulate CD25, and
therefore respond to IL-2, is associated with T cell anergy and tol-
erance. In addition, Tregs constitutively express CTLA-4, which
has been shown to directly control DC maturation and the induc-
tion of T cell tolerance by downregulating B7-1/B7-2 expression
on DCs to block the CD28:B7-1/B7-2 signal (Wing et al., 2008;
Qureshi et al., 2011).
An accepted hypothesis is that anti-CTLA-4 blocking anti-
bodies promote enhanced T cell activation and proliferation to
promote effector cell priming (Chambers et al., 2001; Pardoll
and Drake, 2012). In preclinical models, local RT and CTLA-4
blockade was shown to mediate synergistic effects (Dewan et al.,
2009). Furthermore, in mice concurrently challenged with two
tumors, treatment of one tumor with local RT in combination
with systemic administration of anti-CTLA-4 could induce sig-
niﬁcant growth delay in the second tumor that did not receive
local RT; a process referred to as the abscopal effect (Dewan et al.,
2009). The precise mechanism underlying the abscopal regres-
sion of unirradiated tumors was not investigated, but the results
are consistent with increased priming of tumor antigen-speciﬁc
T cells that subsequently inﬁltrate the tumor. Such an effect would
likely bemediatedbyblocking the engagement of CTLA-4on effec-
tor T cells in the context of heightened cross-priming capacity of
DCs in the dLN (discussed above). Interestingly, data from Dewan
et al. (2009) also reported that a fractionated dose of 8 Gy × 3 was
optimal for induction of an abscopal effect when combined with
anti-CTLA-4, whereas and abscopal effect was not observed when
tumors were treated with 20 Gy × 1 or 6 Gy × 5 alone or in combi-
nation with anti-CTLA-4. Although the authors refer to 8 Gy × 3
as a fractionated schedule, this treatment scheme is probably more
accurately described as hypofractionation. The precise mechanis-
tic basis for the ability of 8 Gy × 3 to properly synergize with
anti-CTLA-4 was not explored, however, the authors did note that
this dose scheme did result in the highest level of inﬁltration and
IFN-γ production by T cells. The synergy between local RT and
CTLA-4 blockade observed in preclinical models appears to trans-
late well into the clinic. Several reports in melanoma patients have
demonstrated abscopal regression following treatment with local
RT and anti-CTLA-4 (ipilimumab) that was associated with ele-
vated immunity to tumor-associated antigens (Postow et al., 2012;
Stamell et al., 2012). At present, there is no clear role for CTLA-
4 blockade in the tumor microenvironment. It is reasonable to
suspect that Tregs expressing CTLA-4 in the tumor microenvi-
ronment could similarly modulate DCs that inﬁltrate the tumor,
however, deﬁnitive evidence that CTLA-4 participates in Treg-
mediated suppression in the tumor microenvironment is lacking.
Strategies that enhance T cell activation by engaging costimulatory
receptors expressedonTcells represent a complimentary approach
to blockade of negative regulators.
Enhancement of effector cell priming is a shared mechanism
between anti-CTLA-4 and other targeted therapies employing
agonistic antibodies against the costimulatory receptors OX40, 4-
1BB (CD137), and CD27 (for a detailed review, see Redmond
et al., 2009). Brieﬂy, stimulation of T cells through OX40 results
in enhanced T cell activation and effector cell differentiation, in
part, through enhancing the expression of CD25 and promot-
ing T cell sensitivity to IL-2. A recent report demonstrated that
agonistic OX40 antibodies in combination with systemic IL-2
administration could generate potent anti-tumor immunity, and
the synergistic nature of the combination resulted from the ability
of systemic IL-2 to upregulateOX40 expression on activated T cells
(Redmond et al., 2012).
Results from a phase I study of stereotactic body radiation
therapy (SBRT) and systemic IL-2 in melanoma and renal cell
carcinoma demonstrated that this combination could result in
impressive responses in both tumor types (Seung et al., 2012).
Addition of OX40 agonistic antibody to this clinical protocol
would be predicted to further enhance responses and perhaps
increase the rate of complete response. Based on these results,
it seems likely that a natural synergy might exist between agonistic
OX40 antibodies and anti-CTLA-4 to induce optimal expression
of CD25 and OX40 and maximize effector T cell differentiation.
Agonistic OX40 antibody has also been shown to synergize with
high dose local RT (20 Gy × 3) and was associated with enhanced
expression of CD25 by tumor-inﬁltrating CD8+ T cells (Gough
et al., 2010). Importantly, OX40 stimulation possesses no inherent
ability to polarize T cells toward one particular effector subset, but
rather, drives T cell polarization in the context of the inﬂammatory
milieu. Considering the nature of most tumor-associated antigens,
it is important to note that costimulation throughOX40 can rescue
priming of low avidity T cells, and can also reverse T cell toler-
ance against self-antigens. Taken together, the mixed preclinical
and clinical data employing local ablative RT with OX40 agonis-
tic antibody, systemic IL-2, or anti-CTLA-4 antibody demonstrate
that signaling through CD25 and OX40 reciprocally reinforce each
other to augment effector cell priming initiated by local RT and
improve the quality and magnitude of T cell responses against
tumor-associated antigens. Future clinical trials that employ local
RT, anti-CTLA-4, and agonistic OX86 are likely to yield impressive
results.
In addition to the goal of improving T cell activation and
effector cell generation, strategies that target immune suppressive
mechanism in the tumor microenvironment are equally impor-
tant. Local RT does have the ability to modify the tumor microen-
vironment, however,many tumors exploit natural immune regula-
tory mechanisms to subvert induced T cells responses. Expression
of programmed death ligand-1 (PD-L1) in the tumor microen-
vironment can deliver an inhibitory signal through it’s receptor
PD-1 that is expressed on a majority of activated effector T cells.
PD-L1 expression has been observed across many tumor types
(Zou and Chen, 2008) where it mediates apoptosis of inﬁltrat-
ing T cells leading to tumor immune evasion (Dong et al., 2002).
Interestingly, PD-L1 expression can be directly induced by IFNs
indicating that effector T cell activity within the tumor microenvi-
ronment can initiate PD-L1 expression as a negative feedback loop
to squelch T cell effector function (Lee et al., 2006). Corroborating
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the role of effector T cell-mediated PD-L1 upregulation, a recent
study in human melanoma demonstrated a strong correlation
between PD-L1 expression and intratumoral T cell inﬁltration
and IFN-γ (Taube et al., 2012). Data in preclinical models sug-
gest that PD-L1 blockade is necessary in some circumstances to
fully uncover anti-tumor immunity that is induced by local RT in
combination with costimulatory receptor engagement. Verbrugge
et al. (2012) demonstrated that local RT combinedwith anti-OX40
could mediate signiﬁcant growth delay of orthotopic AT-3 mam-
mary tumors, however, the addition of anti-PD-L1 was required
to mediate complete tumor regression. Future studies will likely
continue to uncover optimal combinatorial strategies that enhance
the effects of local RT during each phase of the T cell response.
ADDITIONAL CONSIDERATIONS AND CONCLUDING
REMARKS
From the data discussed above it is clear that combination strate-
gies employing high dose ablative RT and immunotherapy hold a
lot of promise for improving anti-tumor immunity and mediating
complete tumor regression. There are many important outstand-
ing questions before RT and immunotherapy can reliably be
combined in cancer therapy. Amongst the most important are
what is (are) the optimal fractionation (dose delivery of radiation)
schemes to increase anti-tumor immunity? Does daily fraction-
ation continuously kill inﬁltrating T cells and/or reduce their
function, or are tumor-inﬁltrating activated T cells functionally
resistant to the low doses employed in traditional fractionation
or hyperfractionated schedules? Does inclusion of the dLNs sup-
press or enhance the immunogenic effects of radiation, and does
the timing of dLN irradiation change the response to treatment
or therapeutic vaccination. What is the optimal “immune activat-
ing” strategy, e.g., high dose cytokines, vaccination, etc.? Answers
to these and other questions may improve the local effects of RT
and help to understand the basis of activating and improving the
local tumor response to RT and the abscopal effect against distant
metastasis.
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